Comparative survival outcomes of lobectomy versus total thyroidectomy in T1 and T2 papillary thyroid cancer with more than five positive lymph nodes

比较甲状腺叶切除术与甲状腺全切除术治疗T1和T2期乳头状甲状腺癌(淋巴结阳性超过5个)的生存结果

阅读:1

Abstract

The surgical approach for papillary thyroid cancer (PTC) by either lobectomy or total thyroidectomy (TT) has long been a topic of debate, especially for patients with intermediate-risk PTC, such as T1 and T2 stage patients with more than five positive lymph node metastases (LNM). This study analyzed a population-based retrospective cohort of T1 and T2 PTC patients with more than five positive LNM from the SEER database (2004-2017), comparing clinicopathologic features and survival outcomes between those undergoing lobectomy and TT. Cox proportional hazards regression analysis to explore prognostic factors of survival. Propensity score matching (PSM) was used to balance covariates. The study included 5,610 patients, with 5,322 (94.87%) receiving TT and 288 (5.13%) undergoing lobectomy. Patients in the TT group had higher rates of N1b stage diagnoses, multifocal lesions, and more lymph nodes examined and more lymph nodes positive. Survival analysis showed no difference in overall survival (OS) between the groups (p = 0.177), but a significant difference in cancer-specific survival (CSS) (p < 0.001). After 1:1 PSM, there were no significant difference in OS (p = 0.089) and CSS (p = 0.350). Additionally, stratified analysis showed no significant difference in OS and CSS between patients treated with TT plus radioactive iodine (RAI) ablation and those who underwent lobectomy (both p > 0.05). This cohort study suggests that T1 and T2 PTC patients with more than five positive LNM have no additional survival benefit of TT over lobectomy. If RAI ablation is not planned, lobectomy may be an effective alternative.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。